Oropharyngeal Carcinoma

There are 23 clinical trials for oropharyngeal carcinoma, of which 17 are open and 6 are completed or closed. Of the trials that contain oropharyngeal carcinoma as an inclusion criterion, 1 is early phase 1 (0 open), 5 are phase 1 (3 open), 5 are phase 1/phase 2 (4 open), 8 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), 1 is phase 3 (1 open), and 2 are no phase specified (1 open).

CDKN2A, HPV, and HLA-A*02 are the most frequent gene inclusion criteria for oropharyngeal carcinoma clinical trials [3].

Trials Investigating Oropharyngeal Carcinoma by Gene and Recruiting Status

Bintrafusp alfa, intensity-modulated radiation therapy, and dpx-e7 hpv vaccine are the most common interventions in oropharyngeal carcinoma clinical trials.

Drugs Being Investigated in Oropharyngeal Carcinoma Trials by Recruiting Status

Significant Genes in Oropharyngeal Carcinoma

ABL1 +

ABL1 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF +

BRAF is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

DDR2 +

DDR2 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DDR2 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR +

EGFR is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EPHA2 +

EPHA2 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 +

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB4 +

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB4 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 +

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2 +

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT1 +

FLT1 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 +

FLT4 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FRK +

FRK is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FRK status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KDR +

KDR is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT +

KIT is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MAPK11 +

MAPK11 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK11 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA +

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB +

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAF1 +

RAF1 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RET +

RET is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TEK +

TEK is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TEK status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TRNAK2 +

TRNAK2 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TRNAK2 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFA +

VEGFA is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFA status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFB +

VEGFB is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFC +

VEGFC is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFC status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Disease Details

Parent(s)

Malignant Oropharyngeal Neoplasm

Children

Oropharyngeal Squamous Cell Carcinoma and Tonsillar Carcinoma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Oropharyngeal Carcinoma

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Oropharyngeal Carcinoma

Disease Details

References

About

Molecular Medicine

Content Types